Document Detail


Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment.
MedLine Citation:
PMID:  3888388     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
One hundred eight patients with stage III non-small cell lung cancer were randomly assigned to receive cisplatin (120 mg/m2) with either vindesine (3 mg/m2) or vinblastine (6 mg/m2). None had previously received chemotherapy. An additional goal was to determine if the observation of visible evaluable lesions was as accurate a method of response assessment as the observation of bidimensionally measurable lesions in non-small cell lung cancer. When vindesine plus cisplatin was compared to vinblastine plus cisplatin, response rates (33% vs 41%), median response durations (8.6 vs 5.6 months), and median survival times of responding patients (18.4 vs 16.2 months) were similar. Response rates, response durations, and survival times of responding patients determined through the observation of evaluable or measurable indicator lesions did not differ significantly. More patients receiving vinblastine plus cisplatin experienced wbc counts less than 2100/mm3 (P = 0.003). The two regimens demonstrated comparable response and survival data but clinically significant leukopenia was more common in vinblastine-treated patients. There was no difference in response data obtained through the study of patients with measurable and evaluable indicator lesions.
Authors:
M G Kris; R J Gralla; L A Kalman; D P Kelsen; E S Casper; M T Burke; S Groshen; I R Cibas; R Bagin; R T Heelan
Related Documents :
21537128 - Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency a...
8075028 - Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (mvp) vs...
21431468 - Gamma knife stereotactic radiosurgery for the management of incidentally-identified bra...
1845848 - Etoposide in the management of non-small cell lung cancer.
18465338 - Long-term outcome after mastectomy with immediate breast reconstruction.
21476178 - Outcome and quality of life favour a conservative treatment of patients with primary ga...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer treatment reports     Volume:  69     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1985 Apr 
Date Detail:
Created Date:  1985-07-11     Completed Date:  1985-07-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  387-95     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy*
Adult
Aged
Carcinoma, Squamous Cell / drug therapy*
Cisplatin / adverse effects,  therapeutic use*
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Humans
Injections, Intravenous
Leukocyte Count
Lung Neoplasms / drug therapy*
Male
Middle Aged
Neoplasm Metastasis
Platelet Count
Random Allocation
Vinblastine / adverse effects,  analogs & derivatives*,  therapeutic use*
Vindesine
Grant Support
ID/Acronym/Agency:
CA-05826/CA/NCI NIH HHS; N01-CM-57043/CM/NCI NIH HHS
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin; 53643-48-4/Vindesine; 865-21-4/Vinblastine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone ...
Next Document:  Ergometry in the assessment of arterial hypertension.